Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
NCT ID: NCT05227534
Last Updated: 2022-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
12500 participants
INTERVENTIONAL
2022-06-01
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT05463796
Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection
NCT06703632
Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection
NCT06620627
Technology-Based Cancer Screening Intervention
NCT04535492
Prevention of Colorectal Cancer Through Multiomics Blood Testing
NCT04369053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will enroll approximately 12,500 participants as defined by eligibility criteria with an anticipated enrollment period of approximately 9 months at up to 30 clinical sites within China. Participants will be actively followed for approximately 5 years from the date of their enrollment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants 40 years of age or older with cancer risk
The study will aim to enroll participants 40 years of age or older with cancer risk. Specific cancer risks will be enriched to increase the number of cancer events that are observed during the study.
OverC multi-cancer detection blood test
Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OverC multi-cancer detection blood test
Blood collection for the OverC multi-cancer detection blood test and standard-of-care screening with return of results
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must not have received any colonoscopy, abdominal MRI/CT, low-dose CT, or chest CT within 5 years before signing the informed consent form
* Participants must be able to provide blood samples for study tests
* Participants must be between 40 and 75 years old
Exclusion Criteria
* Individuals with cancer-associated clinical symptoms or suspected of cancer
* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
* Recipient of blood transfusion within 7 days prior to recruitment
* Individuals who have pure ground-glass opacity
* Unable to provide blood samples for the multi-cancer early detection blood test
* Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests
* Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment
* Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment
* Individuals with hemorrhagic diseases
* Individuals with autoimmune diseases
* Individuals who are pregnant or lactating
* Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers
40 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
West China Hospital
OTHER
Guangzhou Burning Rock Dx Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RSCD2022006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.